La traduzione di questa pagina è sperimentale e in fase di sviluppo. Siamo lieti di ricevere vostro !

Rohto PharmaceuticalLtd Salute del bilancio

Salute finanziaria criteri di controllo 5/6

Rohto PharmaceuticalLtd ha un patrimonio netto totale di ¥257.2B e un debito totale di ¥45.9B, che porta il suo rapporto debito/patrimonio netto a 17.8%. Le sue attività totali e le sue passività totali sono rispettivamente ¥408.7B e ¥151.5B. L'EBIT di Rohto PharmaceuticalLtd è ¥40.3B rendendo il suo rapporto di copertura degli interessi -20.7. Ha liquidità e investimenti a breve termine pari a ¥73.6B.

Informazioni chiave

17.8%

Rapporto debito/patrimonio netto

JP¥45.87b

Debito

Indice di copertura degli interessi	-20.7x
Contanti	JP¥73.62b
Patrimonio netto	JP¥257.25b
Totale passività	JP¥151.49b
Totale attività	JP¥408.73b

Aggiornamenti recenti sulla salute finanziaria

Does Rohto PharmaceuticalLtd (TSE:4527) Have A Healthy Balance Sheet?

Jul 11

These 4 Measures Indicate That Rohto PharmaceuticalLtd (TSE:4527) Is Using Debt Safely

Apr 03

Recent updates

Returns At Rohto PharmaceuticalLtd (TSE:4527) Appear To Be Weighed Down

Sep 22

Here's Why Rohto PharmaceuticalLtd (TSE:4527) Has Caught The Eye Of Investors

Aug 25

Rohto Pharmaceutical Co.,Ltd. Just Missed EPS By 6.8%: Here's What Analysts Think Will Happen Next

Aug 11

Does Rohto PharmaceuticalLtd (TSE:4527) Have A Healthy Balance Sheet?

Jul 11

Calculating The Fair Value Of Rohto Pharmaceutical Co.,Ltd. (TSE:4527)

Jun 23

Unpleasant Surprises Could Be In Store For Rohto Pharmaceutical Co.,Ltd.'s (TSE:4527) Shares

Jun 10

Rohto PharmaceuticalLtd (TSE:4527) Has More To Do To Multiply In Value Going Forward

May 14

These 4 Measures Indicate That Rohto PharmaceuticalLtd (TSE:4527) Is Using Debt Safely

Apr 03

Here's Why We Think Rohto PharmaceuticalLtd (TSE:4527) Is Well Worth Watching

Mar 21

Rohto PharmaceuticalLtd (TSE:4527) Is Paying Out A Larger Dividend Than Last Year

Mar 07

Estimating The Intrinsic Value Of Rohto Pharmaceutical Co.,Ltd. (TSE:4527)

Feb 26

Analisi della posizione finanziaria

Passività a breve termine: Le attività a breve termine ( ¥211.7B ) di 4527 superano le sue passività a breve termine ( ¥119.5B ).

Passività a lungo termine: Le attività a breve termine di 4527 ( ¥211.7B ) superano le sue passività a lungo termine ( ¥31.9B ).

Storia e analisi del rapporto debito/patrimonio netto

Livello di debito: 4527 ha più liquidità del suo debito totale.

Riduzione del debito: Il rapporto debito/patrimonio netto di 4527 è aumentato da 3.3% a 17.8% negli ultimi 5 anni.

Copertura del debito: Il debito di 4527 è ben coperto dal flusso di cassa operativo ( 74.7% ).

Copertura degli interessi: 4527 matura più interessi di quanti ne paga, quindi la copertura dei pagamenti degli interessi non è un problema.

Rohto PharmaceuticalLtd Salute del bilancio

Salute finanziaria criteri di controllo 5/6

Informazioni chiave

Aggiornamenti recenti sulla salute finanziaria

Does Rohto PharmaceuticalLtd (TSE:4527) Have A Healthy Balance Sheet?

These 4 Measures Indicate That Rohto PharmaceuticalLtd (TSE:4527) Is Using Debt Safely

Recent updates

Returns At Rohto PharmaceuticalLtd (TSE:4527) Appear To Be Weighed Down

Upcoming dividend of JP¥16.00 per share

Now 20% undervalued

Rohto Pharmaceutical Co.,Ltd. to Report Q2, 2025 Results on Nov 13, 2024

Here's Why Rohto PharmaceuticalLtd (TSE:4527) Has Caught The Eye Of Investors

Rohto Pharmaceutical Co.,Ltd. Just Missed EPS By 6.8%: Here's What Analysts Think Will Happen Next

First quarter 2025 earnings: Revenues exceed analysts expectations while EPS lags behind

Rohto Pharmaceutical Co.,Ltd. Revises Dividend Guidance for the Second Quarter-End and Full Fiscal Year Ending March 31, 2025

Investor sentiment deteriorates as stock falls 16%

Does Rohto PharmaceuticalLtd (TSE:4527) Have A Healthy Balance Sheet?

Final dividend of JP¥15.00 announced

Now 20% undervalued

Calculating The Fair Value Of Rohto Pharmaceutical Co.,Ltd. (TSE:4527)

Rohto Pharmaceutical Co.,Ltd. to Report Q1, 2025 Results on Aug 07, 2024

Unpleasant Surprises Could Be In Store For Rohto Pharmaceutical Co.,Ltd.'s (TSE:4527) Shares

Rohto Pharmaceutical Co.,Ltd. agreed to acquire 51% stake in Mono chem-pharm Produkte Gmbh for €30 million.

Now 21% undervalued after recent price drop

Full year 2024 earnings: Revenues and EPS in line with analyst expectations

Rohto Pharmaceutical Co.,Ltd., Annual General Meeting, Jun 27, 2024

Rohto PharmaceuticalLtd (TSE:4527) Has More To Do To Multiply In Value Going Forward

Rohto Pharmaceutical Co.,Ltd. to Report Q4, 2024 Results on May 13, 2024

Now 21% undervalued after recent price drop

Now 22% undervalued after recent price drop

Rohto Pharmaceutical Co.,Ltd. (TSE:4527), Mitsui & Co., Ltd. (TSE:8031) and others agreed to acquire an 86% stake in Eu Yan Sang International Ltd from Blanca Investments Pte. Ltd., Tower Capital Asia and founding family for approximately SGD 690 million.

These 4 Measures Indicate That Rohto PharmaceuticalLtd (TSE:4527) Is Using Debt Safely

Upcoming dividend of JP¥15.00 per share

Here's Why We Think Rohto PharmaceuticalLtd (TSE:4527) Is Well Worth Watching

Now 21% undervalued after recent price drop

Rohto PharmaceuticalLtd (TSE:4527) Is Paying Out A Larger Dividend Than Last Year

Estimating The Intrinsic Value Of Rohto Pharmaceutical Co.,Ltd. (TSE:4527)

Third quarter 2024 earnings released: EPS: JP¥41.92 (vs JP¥37.02 in 3Q 2023)

Rohto Pharmaceutical Co.,Ltd. to Report Q3, 2024 Results on Feb 09, 2024

Price target decreased by 7.5% to JP¥3,814

Rohto Pharmaceutical Co.,Ltd. Provides Consolidated Earnings Guidance for the Fiscal Year Ending March 31, 2024

Rohto Pharmaceutical Co.,Ltd. Provides Dividend Guidance for the Full Year Ending March 31, 2024

Second quarter 2024 earnings: EPS and revenues exceed analyst expectations

Rohto Pharmaceutical Co.,Ltd. Declares Dividend for the Second Quarter of Fiscal Ending March 31, 2024, Payable on December 7, 2023

Price target increased by 9.4% to JP¥4,126

Rohto Pharmaceutical Co.,Ltd. to Report Q2, 2024 Results on Nov 10, 2023

Upcoming dividend of JP¥12.00 per share at 0.6% yield

Price target increased by 9.4% to JP¥3,999

Price target increased by 9.0% to JP¥3,884

Investor sentiment improves as stock rises 18%

New minor risk - Share price stability

First quarter 2024 earnings: EPS and revenues exceed analyst expectations

Rohto Pharmaceutical Co.,Ltd. to Report Q1, 2024 Results on Aug 09, 2023

Price target decreased by 13% to JP¥3,206

Full year 2023 earnings: EPS exceeds analyst expectations

Rohto Pharmaceutical Co.,Ltd., Annual General Meeting, Jun 28, 2023

Price target increased by 27% to JP¥3,531

Price target increased by 8.4% to JP¥2,870

Upcoming dividend of JP¥12.00 per share at 0.9% yield

Rohto Pharmaceutical Co.,Ltd. Revises Consolidated Earnings Guidance for the Fiscal Year Ending March 31, 2023

Third quarter 2023 earnings: Revenues exceed analyst expectations

Rohto Pharmaceutical Co.,Ltd. to Report Q3, 2023 Results on Feb 13, 2023

Less than half of directors are independent

Second quarter 2023 earnings: EPS and revenues exceed analyst expectations

Rohto Pharmaceutical Co.,Ltd. to Report Q2, 2023 Results on Nov 10, 2022

Upcoming dividend of JP¥20.00 per share

Rohto Pharmaceutical Co.,Ltd. Provides Consolidated Earnings Guidance for the Fiscal Year Ending March 31, 2023

First quarter 2023 earnings: EPS and revenues exceed analyst expectations

Investor sentiment improved over the past week

Rohto Pharmaceutical Co.,Ltd. to Report Q1, 2023 Results on Aug 09, 2022

Rohto Pharmaceutical Co.,Ltd. Provides Dividend Guidance for the Fiscal Year Ending March 31, 2023

Full year 2022 earnings: EPS and revenues exceed analyst expectations

Consensus forecasts updated

Rohto Pharmaceutical Co.,Ltd., Annual General Meeting, Jun 27, 2022

Consensus forecasts updated

Less than half of directors are independent

Rohto Pharmaceutical Co.,Ltd. to Report Fiscal Year 2022 Results on May 12, 2022

Price target increased to JP¥4,325

Now 21% undervalued

Upcoming dividend of JP¥21.00 per share